Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EGHT gaining investor support.
RTEC up again with new highs $32.70
I still believe it is a prime buyout candidate, as the sector consolidates.
One of a few companies American based in the sector that have not been consumed.
Profits continue significantly.
How much are you paid to pump this dilution machine? Who is selling today?
Truly cannot be many common retail investors left to sell.
Is there a dilution in progress today?
By the way the many years ago story does not fly very well. Cash-burn ratio way out of control regardless. Only hands on the money is and was management.
Naive? They should have used some of their own money, maybe they would not have been so flagrant in spending it dumbfoundedly.
$0.63?
They blame the bad management who mislead them would be the correct statement.
Now that notice is just to show that investors got in to early. Nasdaq now going to teach investors a lesson and slaughter their investments. An investor needs to understand that they are at fault, not the over paid management for running a cash burn ratio of disastrous proportions. In no way is it the company's fault. It is the investors fault for getting into to early.
I truly like writing in sarcastic form.
An acquisition to upgrade quality making a better experience for business with their customers.
GROWTH = MarianaIQ acquisition.
8x8 continues to keep getting bigger and better.
Well the investors like the movement upward. Uncertain what is causing the movement upward other than what has already been laid out.
Nice!
Really? Tomorrow? Unless you have insider news. No reason for it to go up!
The financial press release is "stuffy". I would tend to say, Besides myself liking the products the company has in the working. The financial press release offered nothing in regards to forward financial guidance activity. Smoke screen press release, look here at the future speculation and ignore now. 6 million dollars left in the expense account, and cash burn continues that is logically going to burn the expense account dry.
OPINION WITHOUT INTENDED INSULT.
Just noticed. EGHT hit $23.05 as a new high. Must of been yesterday.
NICE! THe word is NICE!
Just noticed. EGHT hit $23.05 as a new high. Must of been yesterday.
NICE! THe word is NICE!
$22.20 early trading hour. Nice.
EGHT making new 52 highs in the early hour. $22.20. Nice.
MNGA already showed how they sterilize investors.
DUK beats analysis estimates. Taking out the one time expenses. DUKE ENERGY actually produced $1.28 a share, along with growth, and bigger revenue.
"Excluding one-time items, the company earned $1.28 per share, beating analysts' estimate of $1.14 per share, according to Thomson Reuters I/B/E/S.
Total operating revenue rose 7.1 percent to $6.14 billion."
https://finance.yahoo.com/news/duke-energy-quarterly-profit-beats-113341830.html
PGNX moving up favorable. Financials released today with comments.
Yea! Yea! Yea! I meant insight. Oh well! I C-R-E-A-T-E-D.
Deal reached to roll back Dodd-Frank. We should, unless there is a claim that it is already factored in. The roll back could very well excite the financials in a far more bullish manner. I would have to go with a bullish financial sector. Financial funds will truly benefit.
Now this is just my view point.
I guess the boys and girls will be keeping their jobs a while longer.
Excellent incite. Not to mention it might be easily manipulated.
It sure likes to keep a consistent $0.01 a share overall. Earnings fall short year over year on the quarter. Though it does show a positive EPS $0.0090.
Hard stock to even significantly day trade, even though I find the risk minimal, but then it could get nasty. The volume is far from being excitable on average.
I think making fudge might be more fun for the time being. Of course as stocks go, things can always change.
Thanks for the incite.
OPINION.
Another 52 week high. $21.80
SBUX drew out numerous sellers on news. I would expect a retracement with further movement upward once the news gets absorbed and sellers exhaust.
Just watching as a swing trade for now.
SBUX huge deal announced. The share price has now retraced the pre market gap presently.
7 billion dollar deals usually bring out some excitement.
Watching presently
New 52 high. EGHT working $21.50. Oppenheimer $25.
Ratio to target is 16.2% from $21.50 to $25
Nice!
RTEC screaming new highs. Not only are the financials a blow out. Guidance is incredible. RTEC is also a very favorable buy out candidate as consolidation in the industry continues. RTEC being one of a few left in America that has not yet been gobbled up and taking over.
RTEC $31.80
EGHT keeps climbing from upgrades. New highs!
PGNX favorable legal news this morning.
https://finance.yahoo.com/news/summary-judgment-granted-upholding-validity-000500451.html
Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection
GlobeNewswire•May 2, 2018
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX) reported that its partner Valeant Pharmaceuticals International, Inc. today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection. The ruling prevents generic competition in the United States until 2024.
Plaintiffs in the case, including Progenics, Salix Pharmaceuticals, Inc., Valeant and Wyeth LLC, had filed a motion for summary judgment on challenges to the validity of Claim 8 of U.S. Patent No. 8,552,025, which protects the formulation of RELISTOR® Injection.
Defendants in the case, which include Mylan Inc., Mylan Laboratories LTD., Mylan Pharmaceuticals, Inc. and Actavis LLC., had previously stipulated to infringement of Claim 8 and have no remaining invalidity defenses.
In the upcoming trial on June 4, the court is expected to decide the infringement and validity of other patents that could prevent generic RELISTOR® vials until 2029 and generic RELISTOR® syringes until 2030.
About RELISTOR®
Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR, to Valeant. RELISTOR Tablets (450 mg once daily) are approved in the United States for the treatment of opioid-induced constipation (OIC) in patients with chronic non-cancer pain. RELISTOR Subcutaneous Injection (12 mg and 8 mg) is a treatment for OIC approved in the United States and worldwide for patients with advanced illness and chronic non-cancer pain.
IMPORTANT SAFETY INFORMATION - RELISTOR (methylnaltrexone bromide) tablets, for oral use and RELISTOR (methylnaltrexone bromide) injection, for subcutaneous use
RELISTOR tablets and injection are contraindicated in patients with known or suspected gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.
Cases of gastrointestinal perforation have been reported in adult patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract (e.g., peptic ulcer disease, Ogilvie's syndrome, diverticular disease, infiltrative gastrointestinal tract malignancies or peritoneal metastases). Take into account the overall risk-benefit profile when using RELISTOR in patients with these conditions or other conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g., Crohn's disease). Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue RELISTOR in patients who develop this symptom.
If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their healthcare provider.
Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, and yawning have occurred in patients treated with RELISTOR. Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal and/or reduced analgesia and should be monitored for adequacy of analgesia and symptoms of opioid withdrawal.
Avoid concomitant use of RELISTOR with other opioid antagonists because of the potential for additive effects of opioid receptor antagonism and increased risk of opioid withdrawal.
The use of RELISTOR during pregnancy may precipitate opioid withdrawal in a fetus due to the immature fetal blood brain barrier and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the potential for serious adverse reactions, including opioid withdrawal, in breastfed infants, advise women that breastfeeding is not recommended during treatment with RELISTOR. In nursing mothers, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
A dosage reduction of RELISTOR tablets and RELISTOR injection is recommended in patients with moderate and severe renal impairment (creatinine clearance less than 60 mL/minute as estimated by Cockcroft-Gault). No dosage adjustment of RELISTOR tablets or RELISTOR injection is needed in patients with mild renal impairment.
A dosage reduction of RELISTOR tablets is recommended in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment. No dosage adjustment of RELISTOR tablets is needed in patients with mild hepatic impairment (Child-Pugh Class A). No dosage adjustment of RELISTOR injection is needed for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, monitor for methylnaltrexone-related adverse reactions.
In the clinical studies, the most common adverse reactions were:
OIC in adult patients with chronic non-cancer pain
RELISTOR tablets (≥ 2% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (14%), diarrhea (5%), headache (4%), abdominal distention (4%), vomiting (3%), hyperhidrosis (3%), anxiety (2%), muscle spasms (2%), rhinorrhea (2%), and chills (2%).
RELISTOR injection (≥ 1% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (21%), nausea (9%), diarrhea (6%), hyperhidrosis (6%), hot flush (3%), tremor (1%), and chills (1%).
OIC in adult patients with advanced illness
RELISTOR injection (≥ 5% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (29%) flatulence (13%), nausea (12%), dizziness (7%), and diarrhea (6%).
Please see complete Prescribing Information for RELISTOR at www.valeant.com. For more information about RELISTOR, please visit www.RELISTOR.com.
About Progenics
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
This press release contains projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs, including our NDA for AZEDRA; market acceptance for approved products; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission, including those risk factors included in its Annual Report on Form 10-K for the annual period ended December 31, 2017. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Information on or accessed through our website or social media sites is not included in the company's SEC filings.
(PGNX-F)
Contact: Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com
RTEC screaming with bonus financials! Kaboooooom!
Rudolph Technologies beats by $0.11, beats on revenue
May 2, 2018 4:21 PM ET
Rudolph Technologies (NASDAQ:RTEC): Q1 EPS of $0.51 beats by $0.11.
Revenue of $73.09M (+20.5% Y/Y) beats by $4.16M.
Gettel owns 17 automotive dealerships throughout Florida, including Acura, BMW, Buick-GMC, Chevrolet, Chrysler, Dodge, Hyundai, Jeep, Lincoln, Mitsubishi, Nissan, Porsche, Ram, Toyota and Volkswagen.
https://www.gettel.com/locations/index.htm
8x8, Inc. to Announce Fourth Quarter and Full-Year Fiscal 2018 Financial Results on May 24, 2018 (Thursday). After-market close.
Why is the company working on labeling with the FDA prior to approval? Is there going to be a black box warning? Is my guess good?
EGHT sitting at $20.25. Nice move from the Oppenheimer upgrade.
“Real generosity is doing something nice for someone who will never find out.”
8X8 Price Target Announced at $25.00/Share by Oppenheimer
April 19, 2018
08:15 AM ET
"8x8, Inc. initiated with an Outperform at Oppenheimer.
Oppenheimer analyst Timothy Horan started 8x8, Inc. with an Outperform rating and $25 price target. The company is well positioned to capture share in the fast-growing UCaaS/Collaboration market, Horan tells investors in a research note. The analyst expects accelerating adoption of UCaaS and says 8x8 has the most experience and largest breadth of services versus peers.
Source: theflyonthewall.com"
Note:
Borrowed this post from Yahoo Finance EGHT message board.
Oppenheimer Upgrade! Superb!
Must be very reputable to influence a new 52 week high, even though after hour. I appreciate the informative posting. When did the FlyOnTheWall issue the upgrade? Was there any commentary to go along with the upgrade?
I appreciate the due diligence as I wait on this reversed split time bomb.
EGHT: $20.90 up 7.18% in after hours. Volume 16,583. Highly unusual after hour retail activity. $20.25 is the 52 week high.
kaboooooooooooooooom!
EGHT: $20.90 up 7.18% in after hours. Volume 16,583. Highly unusual after hour retail activity. $20.25 is the 52 week high.
EGHT: $20.90 up 7.18% in after hours. Volume 16,583. Highly unusual after hour retail activity. $20.25 is the 52 week high.